Investigation Launched into Voyager Therapeutics Over Possible Securities Violations
The Schall Law Firm, which specializes in shareholder rights litigation, is investigating potential claims from investors regarding Voyager Therapeutics, Inc. (“Voyager” or “the Company”) VYGR. The inquiry centers on possible violations of securities laws.
Concerns About Company Transparency
The investigation will determine if Voyager made false or misleading statements or failed to share crucial information with investors. On February 11, 2025, Voyager released a statement indicating that it is reevaluating its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The Company revealed that “emerging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.” Consequently, Voyager stated it “no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025.” Following this announcement, Voyager’s shares dropped by 20% on the same day.
If you are a shareholder who has incurred losses, we invite you to reach out and participate in this investigation.
Legal Consultation Offered
Brian Schall of the Schall Law Firm encourages affected shareholders to contact him at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335 for a free discussion about their rights. Additionally, you can visit the firm’s website at www.schallfirm.com, or email at bschall@schallfirm.com.
The Schall Law Firm provides representation for investors globally and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in certain jurisdictions under applicable law and ethical standards.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20250220435070/en/
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
Market News and Data brought to you by Benzinga APIs
